Breaking News: Novartis Temporarily Modifies U.S. Mobile Administration Program for Sandostatin LAR During Pandemic

Due to the COVID-19 pandemic and Novartis’ ongoing commitment to support patients,  Novartis has temporarily modified the eligibility criteria related to their U.S. mobile administration program (MAP) to allow for use by patients currently receiving Sandostatin LAR therapy, regardless of insurance plan or state of residency.

The MAP provides in home administration of Sandostatin LAR at no charge to patients or their health insurance plans.  As part of the program, the patient works with their physician and pharmacy to purchase the product and have it shipped to their home. The program will coordinate a visit by a trained nurse upon receipt of the product by the patient.  The nurse will come to a patient’s home to prepare and administer the Sandostatin LAR Depot.  It is important to note that not all insurance plans cover having the product administered in a home setting, and therefore, it is important that the patient discusses home administration with their physician and insurance plan.

As with all care decisions, it is recommended that patients talk to their doctor about how to manage their Sandostatin LAR treatments.  To participate in the mobile administration program, the patient and physician will need to complete the electronic service request form (SRF) on the Novartis Patient Assistance Now Oncology (PANO) website and arrange for the purchase and delivery of the product. For further information, call 1-800-282-7630.

Breaking News_3


Print Friendly, PDF & Email